Artiva Biotherapeutics reported net income of -$25.01M for the quarter ended Jun 2026. This income statement covers 13 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.81M | 0.81M | 0.81M | 0.81M | 0.81M | 18.90M | 11.26M | 24.36M | 24.43M | 24.54M | 24.72M | 24.72M | 39.41M |
| Revenue & cost | |||||||||||||
| Revenue | 3.50M | 26.66M | 2.35M | 0.25M | |||||||||
| Operating items | |||||||||||||
| Research & DevelopmentR&D | 11.26M | 13.06M | 11.15M | 11.16M | 12.33M | 13.52M | 13.32M | 17.05M | 17.86M | 17.63M | 16.99M | 19.31M | 21.93M |
| Selling, General & AdministrativeSG&A | 4.06M | 2.78M | 3.17M | 3.59M | 3.86M | 4.81M | 4.95M | 5.12M | 4.95M | 5.26M | 4.94M | 5.12M | 4.96M |
| Operating ExpensesOpex | 15.32M | 15.85M | 14.32M | 14.74M | 16.19M | 18.34M | 18.27M | 22.17M | 22.81M | 22.90M | 21.93M | 24.43M | 26.89M |
| Operating IncomeOp. Inc | -11.82M | 10.81M | -11.97M | -14.49M | -16.19M | -18.34M | -18.27M | -22.17M | -22.81M | -22.90M | -21.93M | -24.43M | -26.89M |
| EBIT | -11.82M | 10.81M | -11.97M | -14.49M | -16.19M | -18.34M | -18.27M | -22.17M | -22.81M | -22.90M | -21.93M | -24.43M | -26.89M |
| Non-operating items | |||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.51M | 0.42M | 0.58M | 0.65M | 0.68M | 1.85M | 2.18M | 1.86M | 1.56M | 1.37M | 1.16M | 0.91M | 1.89M |
| Other Non Operating IncomeOther Non Op Inc. | 0.03M | 0.05M | 3.08M | -0.27M | -2.35M | -0.98M | -0.00M | -0.01M | -0.00M | -0.00M | 0.00M | -0.00M | |
| Non Operating IncomeNon Op. Inc. | 0.54M | 0.47M | 0.04M | 0.53M | -1.65M | 0.86M | 2.17M | 1.86M | 1.56M | 1.37M | 1.16M | 0.91M | 1.89M |
| Net income details | |||||||||||||
| EBT | -11.31M | 11.23M | -11.39M | -13.84M | -15.51M | -16.49M | -16.09M | -20.31M | -21.25M | -21.52M | -20.77M | -23.52M | -25.00M |
| Profit After TaxPAT | -11.28M | 11.42M | -12.00M | -13.96M | -17.84M | -17.47M | -16.53M | -20.31M | -21.25M | -21.53M | -20.77M | -23.52M | -25.01M |
| Income from Continuing OperationsIncome (Continuing) | -11.31M | 11.23M | -11.39M | -13.84M | -15.51M | -16.49M | -16.09M | -20.31M | -21.25M | -21.52M | -20.77M | -23.52M | -25.00M |
| Consolidated Net IncomeConsol Net Inc. | -11.31M | 11.23M | -11.39M | -13.84M | -15.51M | -16.49M | -16.09M | -20.31M | -21.25M | -21.52M | -20.77M | -23.52M | -25.00M |
| Income towards Parent CompanyParent Net Inc | -11.31M | 11.23M | -11.39M | -13.84M | -15.51M | -16.49M | -16.09M | -20.31M | -21.25M | -21.52M | -20.77M | -23.52M | -25.00M |
| Net Income towards Common StockholdersNet Income | -11.31M | 11.23M | -11.39M | -13.84M | -15.51M | -16.49M | -16.09M | -20.31M | -21.25M | -21.52M | -20.77M | -23.52M | -25.00M |
| Additional items | |||||||||||||
| EPS (Basic) | -14.13 | 13.92 | -14.19 | -17.09 | -19.12 | -0.87 | -1.43 | -0.83 | -0.87 | -0.88 | -0.85 | -0.95 | -0.63 |
| EPS (Diluted) | -14.13 | 1.61 | -14.19 | -17.09 | -19.12 | -0.87 | -1.43 | -0.83 | -0.87 | -0.88 | -0.85 | -0.95 | -0.63 |
| Shares Outstanding | 0.80M | 0.81M | 0.80M | 0.81M | 0.81M | 18.90M | 11.26M | 24.34M | 24.38M | 24.48M | 24.44M | 24.68M | 39.41M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.80M | 6.97M | 0.80M | 0.81M | 0.81M | 18.90M | 11.26M | 24.34M | 24.38M | 24.48M | 24.44M | 24.68M | 39.41M |
| EBITDA | -11.82M | 10.81M | -11.97M | -14.49M | -16.19M | -18.34M | -18.27M | -22.17M | -22.81M | -22.90M | -21.93M | -24.43M | -26.89M |